* Building on its success in developing continuous production at pilot-scale with the WuXiUP™ pla...
* WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quali...
* Earns CDP's highest rating for supply chain engagement on climate * Adds to other CDP recognit...
* Innovative modular design will accelerate construction and manufacturing timelines, enabling ra...
* Best ESG rating tier of negligible-risk with a top 1% global ranking score * Industry and Regi...
* The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to en...
* Contributing to United Nations Sustainable Development Goals * Enhancing transparency and effe...
* Firm commitment to tackling climate change in support of United Nations Sustainable Development...
- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,...
SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...
* Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY * Adjusted...
* Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development ...
* Ranking in top 1% of S&P Global CSA Score * Inclusion in Global Yearbook for third consecutive...
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysog...
WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ...
WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ...
* Ranked among the top 1% of more than 150,000 companies across 185 countries * Trusted by globa...
* Ranked among the top 1% of companies assessed in the pharmaceutical industry * Recognized as a ...
SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a lead...
* Named for second consecutive year named to prestigious DJSI list * Leading green biologics sol...